Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310594 · ClinicalTrials.gov registry record
Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- 139
- Enrollment target
NCT02310594: Clinical Trial study, sponsored by Jonsson Comprehensive Cancer Center.
NCT02310594 is a clinical trial that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02310594 was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- 139 participants
- Enrollment target
Study Summary
This research trial studies the effect of radiation therapy on tumor immunity. Standard radiation therapy destroys tumor cells. In response to tumor cell death caused by radiation therapy, the body has an ability to stimulate an anti-tumor response (immunity), but this response is often ineffective in shrinking tumor tissue. Collecting samples of blood from patients before, during, and after radiation therapy to study in the laboratory may help doctors learn more about the effects of radiation therapy on anti-tumor response.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2010-07-08 |
| Est. Completion | 2022-08-09 |
Why NCT02310594 stopped before completion
NCT02310594 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02310594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02310594 about?
NCT02310594 is a clinical study titled "Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy". This research trial studies the effect of radiation therapy on tumor immunity. Standard radiation therapy destroys tumor cells. In response to tumor cell death caused by radiation therapy, the body has an ability to stimulate an anti-tumor response (immunity), but this response is often ineffective ...
What is the current status of trial NCT02310594?
This trial is currently terminated. The enrollment target is 139 participants. The study started on 2010-07-08. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT02310594?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER).
Who is sponsoring clinical trial NCT02310594?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI